Skip to main content

Table 2 Prevalence of drug resistance among PLWH with virological failure on ART

From: Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study

 

TDF + 3TC + NVP/EFV

AZT + 3TC + NVP/EFV

LPV/r + 3TC + AZT/TDF

Others

Total

n = 928 (%)

n = 318 (%)

n = 47 (%)

N = 283 (%)

N = 1576 (%)

PIs

13 (1.40)

9 (2.83)

1 (2.13)

6 (2.12)

35 (2.22)

 ATV/r

1 (0.35)

2 (0.13)

 DRV/r

 FPV/r

1 (0.31)

1 (0.35)

3 (0.19)

 IDV/r

1 (0.35)

2 (0.13)

 LPV/r

1 (0.35)

2 (0.13)

 NFV

1 (0.11)

1 (0.31)

2 (0.71)

6 (0.38)

 SQV/r

1 (0.35)

2 (0.13)

 TPV/r

12 (1.29)

8 (2.52)

1 (2.13)

5 (1.77)

31 (1.97)

NRTIs

97 (10.45)

55 (17.30)

2 (4.26)

39 (13.78)

232 (14.72)

 ABC

92 (9.91)

55 (17.30)

2 (4.26)

39 (13.78)

227 (14.40)

 AZT

26 (2.80)

22 (6.92)

2 (4.26)

8 (2.83)

66 (4.19)

 D4T

44 (4.74)

26 (8.18)

2 (4.26)

19 (6.71)

110 (6.98)

 DDI

45 (4.85)

25 (7.86)

2 (4.26)

19 (6.71)

110 (6.98)

 FTC

91 (9.81)

55 (17.30)

2 (4.26)

39 (13.78)

226 (14.34)

 3TC

91 (9.81)

55 (17.30)

2 (4.26)

39 (13.78)

226 (14.34)

 TDF

30 (3.23)

18 (5.66)

1 (2.13)

16 (5.65)

81 (5.14)

NNRTIs

269 (28.99)

108 (33.96)

10 (21.28)

90 (31.80)

567 (35.98)

 EFV

261 (28.13)

103 (32.39)

10 (21.28)

88 (31.10)

550 (34.90)

 ETR

63 (6.79)

42 (13.21)

1 (2.13)

24 (8.48)

154 (9.77)

 NVP

261 (28.13)

105 (33.02)

10 (21.28)

88 (31.10)

552 (35.03)

 RPV

96 (10.34)

58 (18.24)

1 (2.13)

35 (12.37)

225 (14.28)

  1. TDF Tenofovir, 3TC Lamivudine, NVP Nevirapine, EFV Efavirenz, AZT Zidovudine, LPV/r Fosamprenavir/ritonavir, ATV/r Atazanavir/ritonavir, DRv/r Darunavir/ritonavir, FPV/r Fosamprenavir/ritonavir, IDV/r Indinavir/Ritonavir, NFV Nelfinavir, SQV/r Ritonavir-boosted saquinavir, TPV/r Tipranavir/ritonavir, ABC Abacavir, D4T Stavudine, DDI Didanosine, FTC Emtricitabine, ETR Etravirine, RPV Rilpivirine